Click here to Download Data Sheet Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Tribex 5% Oral Suspension for Sheep 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains Active substance: 50mg Triclabendazole Excipient(s): 2.0mg Methyl Parahydroxybenzoate (E2I8) 0.2mg Propyl Parahydroxybenzoate (E216) 17.5 microgram Brilliant Blue (E133). For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Oral suspension An aqueous blue-coloured suspension. 4 CLINICAL PARTICULARS 4.1 Target Species Sheep 4.2 Indications for use, specifying the target species The product is indicated for the treatment of acute, sub-acute and chronic fasciolosis in sheep caused by early immature, immature and adult stages of liverfluke (Fasciola hepatica) susceptible to triclabendazole. 4.3 Contraindications Do not use in cases of known hypersensitivity to the active ingredient 4.4 Special warnings for each target species None 4.5 Special precautions for use Special precautions for use in animals Only use for liver fluke strains susceptible to triclabendazole. Frequent and repeated use may lead to the development of resistance. Care must be taken not to damage the mouth or pharyngeal region when dosing. Clean drenching equipment before and after use. Use unaltered product from the original container. Anthelmintics are agents that destroy or result in the expulsion of susceptible parasitic worms. Parasite resistance to a particularm class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class. To reduce this risk, dosing programmes should be discussed with a veterinary surgeon. Tribex contains the anthelmintic Triclabendazole. Fluke (Fasciola hepatica) resistance to triclabendazole has been identified and losses associated with resistant strains of fluke in sheep flocks treated with triclabendazole can be significant. If signs of fascioliasis continue after treatment with Tribex, DO NOT REPEAT THE DOSE and do not dose with other products containing triclabendazole. Seek veterinary advice. If resistance is suspected or confirmed, you should change active ingredient on veterinary advice. Special precautions to be taken by the person administering the veterinary medicinal product to animals When using the product do not eat, drink or smoke, Wear gloves. Wash splashes from eyes and skin immediately. Take off any contaminated clothing immediately. Wash hands and exposed skin before meals and after work. In cases of hypersensitivity and contact allergy, direct skin contact and inhalation should be avoided. 4.6 Adverse reactions (frequency and seriousness) None known 4.7 Use during pregnancy, lactation or lay The product can be safely given to pregnant sheep. Do not administer to sheep producing milk for human consumption. 4.8 Interaction with other medicinal products and other forms of interaction None known. 4.9 Amounts to be administered and administration route For oral administration only, using properly calibrated dosing equipment. Estimate bodyweight accurately. Shake container before use. Recommended dose rate: 10 mg triclabendazole per kg bodyweight as a single administration. DOSAGE GUIDE: For animals over 80 kg - give an additional 2 ml for each additional 10 kg bodyweight DOSING PROGRAMME: Routine treatment (Areas of heavy fluke infection) As a guide, dose all sheep exposed to fluke infected pastures preventatively at regular intervals of 10 weeks from March/April through to October/November. In situations where stock are out-wintered, another dose in January may be required. All animals grazing the pasture should be treated at these times. All bought in animals should be dosed before joining the main flock. Veterinary advice should be sought with regard to specific preventative dosing regimes. Routine treatment (Areas of moderate fluke infection) Dose all sheep on fluke infected pastures at intervals of 10 weeks throughout the fluke season, usually September to January/February. All bought in animals should be dosed before joining the main flock. An additional preventative treatment in the spring will assist in reducing the amount of new infestation on pasture in the following autumn. Treatment of acute outbreaks The flock should be treated immediately after diagnosis and veterinary advice should be sought for subsequent dosing intervals. If a preventative fluke dosing programme is employed, the occurrence of acute fluke is greatly reduced. Re-treatment may not be out within 8 weeks. 4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary No adverse effects were reported following a dose of 12.5 times the recommended dose. At higher doses (up to 20-fold), mild transient ataxia and weight loss were observed in some animals 3-6 days after treatment. 4.11Withdrawal Period(s) Meat and offal: 56 days. Not permitted for use in lactating animals producing milk for human consumption. 5 PHARMACOLOGICAL or IMMUNOLOGICAL PROPERTIES Pharmacotherapeutic group: Anthelmintics, Benzimidazoles and related substances ATC vet-code: QP52ACOI Bodyweight Dosage Up to 10 kg 2 ml 15 kg 3 ml 20 kg 4 ml 25 kg 5 ml 30 kg 6 ml 40 kg 8 ml 50 kg 10 ml 60 kg 12 ml 70 kg 14 ml 80 kg 16 ml 5.1 Pharmacodynamic properties Triclabendazole differs from other benzimidazoles in that it is a narrow spectrum anthelmintic. The drug accumulates significantly in both immature and adult stages of Fasciola hepatica and stimulates the major routes of the parasite’s energy generating system, as demonstrated by glucose derived acetate and propionate formation. However, under these conditions the parasite’s motility decreased, indicating that the drug is not associated with inhibition of the energy generating pathways. Triclabendazole inhibits colchicine binding to microtubular proteins suggesting interference of the drug with microtubular structure and function. The drug strongly inhibits the release of proteolytic enzymes in immature and adult parasites, a process dependant on microtubular functions. The precise molecular mode of action of this fasciolicidal drug remains to be elucidated. 5.2 Pharmacokinetic properties After oral administration, triclabendazole is rapidly metabolised to its sulphoxide and sulphone metabolites. The sulphoxide is thought to be the active moiety. In sheep the sulphoxide and sulphone metabolites reached a Cmax of approx. 13 microgram/ml and 11 microgram/ml at 18 and 30 hours, respectively. The vast majority of orally administered triclabendazole is eliminated in faeces after 7 days. Urinary excretion is minimal. 6 PHARMACEUTICAL PARTICULARS 6.1 List of excipients 70% non-crystallising sorbitol, (E420) Methyl hydroxybenzoate, (E218) Propyl hydroxybenzoate, (E216) Polysorbate 80, (E433) Aluminium Magnesium silicate Microcrystalline cellulose & Carmellose sodium, (E460 and E466) Brilliant blue (E133) Simethicone emulsion Purified water 6.2 Incompatibilities None known. 6.3 Shelf-life Shelf life of the veterinary medicinal product as packaged for sale: 18 months 6.4 Special precautions for storage Do not store above 25°C. Protect from frost. 6.5 Nature and composition of immediate packaging Pack sizes: IL pack contains 0.8L of product, 2.5L pack contains 2.2L of product, 5L pack contains 5L of product Container: High density polyethylene Closure: Copolymer polypropylene with tamper evident seal Cap Liner: Polyfaced Steran Wad Spout: Polypropylene Not all pack sizes may be marketed. 6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. 8 MARKETING AUTHORISATION NUMBER(S) VPA 10879/013/001 9 DATE OF THE FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 20th June 2007 10 DATE OF REVISION OF THE TEXT 27th June 2011
